THERAPY DOSSIER · th-cf3c8b9e511e

Caspase-3 specific inhibitor, with recombinant caspase-3 and LRRTM1 shRNA knockdown as mechanistic arms

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Fracture
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 33069813 ↗2020Reported benefit

Spinal caspase-3 contributes to tibial fracture-associated postoperative allodynia via up-regulation of LRRTM1 expression in mice.

MouseFractureTibiaC57BL/6MaleIntrathecal

Model: Tibial fracture with intramedullary pinning as a model of postoperative pain

Spinal caspase-3 inhibition prevented fracture-associated mechanical and cold allodynia in a dose-dependent manner and reduced the spinal rise in LRRTM1, while intrathecal recombinant caspase-3 induced hypersensitivity that was reversed by LRRTM1 knockdown.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…